Does the use of sodium zirconium cyclosilicate in dialysis patients reduce cardiovascular risk? Is this treatment appropriate?

No direct evidence for reducing cardiovascular risk with sodium zirconium cyclosilicate in dialysis patients. It effectively manages hyperkalemia, potentially offering indirect cardiovascular benefits by enabling RAASi therapy.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24372307
Primary Topic
Potassium and Related Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Does the use of sodium zirconium cyclosilicate in dialysis patients reduce cardiovascular risk? Is this treatment appropriate?

Tripdatabase
Zenodo (CERN European Organization for Nuclear Research)
Potassium and Related Disorders
article

Does the use of sodium zirconium cyclosilicate in dialysis patients reduce cardiovascular risk? Is this treatment appropriate?

Tripdatabase
article en

Abstract

No direct evidence for reducing cardiovascular risk with sodium zirconium cyclosilicate in dialysis patients. It effectively manages hyperkalemia, potentially offering indirect cardiovascular benefits by enabling RAASi therapy.

Zenodo (CERN European Organization for Nuclear Research)
Potassium and Related Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon